AM-Pharma
AM-Pharma develops ilofotase alfa as a potential enzyme replacement therapy for adult hypophosphatasia (HPP) patients.
AM-Pharma has raised €12M across 1 funding round from 4 investors, most recently a Series D+ round in Sep 2014. Based in Utrecht, Netherlands; active in Healthtech. Data as of 28 Oct 2026.
Utrecht, Netherlandsam-pharma.com ↗
Total raised
€12M
€12,200,000
Funding rounds
1
Investors
4
distinct backers
Active since
2014-09
latest 2014-09
Funding by year
EUR raised per yearAM-Pharma — funding by year — interactive chart.
Data table
| AM-Pharma — funding by year | |
|---|---|
| 2014 | €12M |
Signals
High confidenceRaise-next likelihood10
base rate 53% for Series D+
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2014-09-01 | Series D+ | €12M | Abbvie Biotech Ventures,Gilde Healthcare,Inventages Venture Capital,Ysios Capital | View deal → |
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Picnic€1.7BNetherlands · E-commerce
- Just Eat Takeaway€1.6BNetherlands · Foodtech
- Nebius€1.5BNetherlands · Cloud
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData